Search For "bharat biotech"
Updated : 2 weeks, 1 day ago IST
Paris [France], June 19 (ANI): Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday (local time) said that the clinical phase III trials of the COVID-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCG
Updated : 2 weeks, 3 days ago IST
Hyderabad (Telangana) [India], June 17 (ANI): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press
Updated : 3 weeks, 4 days ago IST
New Delhi [India], June 9 (ANI): Prime Minister Narendra Modi will inaugurate the Biotech Startup Expo - 2022 at Pragati Maidan, New Delhi today at 10:30 am.
Updated : 1 month, 1 week ago IST
New Delhi [India], May 26 (ANI): German Ambassador to India, Walter J Lindner, on Thursday hailed the German government for recognizing the WHO-listed Bharat Biotech's COVID vaccine, COVAXIN, for travel to the country starting June 1.
Malvern (Pennsylvania) [US], May 23 (ANI): Biotechnology company Ocugen on Monday announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the Company's Phase 2, 3 clinical trials for COVAXIN™ (BBV152).
Updated : 1 month, 3 weeks ago IST
Oslo [Norway], May 10 (ANI): The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday announced the latest award under its USD 200 m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other beta coronaviruses.
Updated : 2 months ago IST
New Delhi [India], May 4 (ANI): Hyderabad-based pharma company Bharat Biotech has sought permission from the Drugs Controller General of India (DCGI) to conduct trials of Covaxin as COVID-19 vaccine booster dose in the 2-18 age group, sources said.
New Delhi [India], April 29 (ANI): The Minstry of External Affairs has said that media reports purportedly quoting a communication from the ministry asking vaccine maker Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval (EUA) nod for its COVID jab, "potra
Updated : 2 months, 1 week ago IST
New Delhi [India], April 26 (ANI): The Drugs Controller General of India (DCGI) on Tuesday granted an emergency use authorisation (EUA) to Bharat Biotech's Covaxin for the age group of 6-12 years.
Hyderabad (Telangana) [India], April 26 (ANI): The Drugs Controller General of India (DCGI) on Tuesday granted an emergency use authorisation (EUA) to Bharat Biotech's Covaxin for the age group of 6-12 years.
New Delhi [India], April 26 (ANI): The Drugs Controller General of India (DCGI) gives restricted emergency use authorisation to Covaxin for the 6-12 age group.
New Delhi [India], April 22 (ANI): The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has asked Bharat Biotech for additional data on its COVID-19 vaccine, Covaxin, for administering it to children aged between 2-12 years, sources said.